Tyra Biosciences Inc (TYRA) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access TYRA Annual Balance Sheets →
Balance sheet patterns shown here provide context for understanding Tyra Biosciences Inc's financial stability and long-term positioning.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent73.84
Cash, Cash Equivalents Other0.12
Marketable Securities, Total MA280.11
Cash & Short-term Investments353.00
Prepaid Expense And Other Assets Current13.02
Total Current Assets366.97
Equipment/Property/Plant Net1.17
Other Assets, Noncurrent15.22
Restricted Cash Noncurrent0.88
Right Of Use Asset5.44
Total Assets383.36
Liabilities
Accounts Payable, Current AC2.33
Other Accrued Liabilities, Current27.77
Other Liabilities, Current0.00
Total Current Liabilities24.62
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Operating Lease Liability Current0.49
Operating Lease Liability Noncurrent5.21
Total Liabilities29.70
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock810.36
Retained Earnings / Accumulated Deficit-456.12
Accumulated Other Comprehensive Income-0.58
Other Equity-0.58
Common Stockholder's Equity353.66
Total Stockholder's Equity353.66
Liabilities & Stockholder's Equity383.36
4 historic quarters locked

Sign in to unlock the full Tyra Biosciences Inc balance sheet history.

About Tyra Biosciences Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-332995

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.